Sign in or Register   Sign in or Register
  |  

Mouse Anti-PTDSS1 Recombinant Antibody (B-5) (CBMAB-P3299-YC)

Provided herein is a Mouse monoclonal antibody against Human Phosphatidylserine synthase 1. The antibody can be used for immunoassay techniques, such as WB, IP, IF, ELISA.
See all PTDSS1 antibodies

Summary

Host Animal
Mouse
Specificity
Human, Mouse, Rat
Clone
B-5
Antibody Isotype
IgG
Application
WB, IP, IF, ELISA

Basic Information

Specificity
Human, Mouse, Rat
Antibody Isotype
IgG
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at 4°C short term (1-2 weeks). Aliquot and store at-20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Phosphatidylserine synthase 1
Introduction
PTDSS1 catalyzes the formation of phosphatidylserine from either phosphatidylcholine or phosphatidylethanolamine. Phosphatidylserine localizes to the mitochondria-associated membrane of the endoplasmic reticulum, where it serves a structural role as well as a signaling role. Defects in this gene are a cause of Lenz-Majewski hyperostotic dwarfism.
Entrez Gene ID
Human9791
Mouse19210
Rat314553
UniProt ID
HumanP48651
MouseQ99LH2
RatQ5PQL5
Alternative Names
LMHD; PSS1; PSSA
Function
Catalyzes a base-exchange reaction in which the polar head group of phosphatidylethanolamine (PE) or phosphatidylcholine (PC) is replaced by L-serine (PubMed:19014349, PubMed:24241535).
Catalyzes mainly the conversion of phosphatidylcholine (PubMed:19014349, PubMed:24241535).
Also converts, in vitro and to a lesser extent, phosphatidylethanolamine (PubMed:19014349, PubMed:24241535).
Biological Process
Phosphatidylserine biosynthetic processManual Assertion Based On ExperimentIDA:FlyBase
Involvement in disease
Lenz-Majewski hyperostotic dwarfism (LMHD):
A syndrome of intellectual disability and multiple congenital anomalies that features generalized craniotubular hyperostosis. LMHD is characterized by the combination of sclerosing bone dysplasia, intellectual disability and distinct craniofacial, dental, cutaneous and distal limb anomalies. The progressive generalized hyperostosis associated with this syndrome affects the cranium, the vertebrae and the diaphyses of tubular bones, leading to severe growth restriction.
Topology
Cytoplasmic: 2-35
Helical: 36-56
Lumenal: 57-72
Helical: 73-93
Cytoplasmic: 94-102
Helical: 103-123
Lumenal: 124-186
Helical: 187-207
Cytoplasmic: 208-216
Helical: 217-237
Lumenal: 238-286
Helical: 287-307
Cytoplasmic: 308-319
Helical: 320-342
Cytoplasmic: 343-355
Helical: 356-376
Lumenal: 377-383
Helical: 384-404
Cytoplasmic: 405-473
Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-PTDSS1 Recombinant Antibody (B-5)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare